This deal will see Organon acquire Roivant’s dermatology business, including its pipeline of promising drug candidates, and its established manufacturing facilities. The acquisition is a strategic move for Organon, aiming to diversify its portfolio and strengthen its position in the U.S. dermatology market. The deal also marks a significant step forward for Roivant, which has been struggling to gain traction in the U.S. market.
Dermavant’s success with Vtama has positioned them as a leader in the psoriasis treatment market. Dermavant Sciences is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for dermatological conditions. They are known for their expertise in the field of dermatology and their commitment to developing effective and safe treatments for patients suffering from various skin conditions.
**A. The Immune System’s Attack on Healthy Skin**
**B.
The condition is characterized by red, scaly patches of skin. Psoriasis is a chronic autoimmune disease, meaning it’s a long-term condition that causes the body’s immune system to attack healthy skin cells. This attack leads to the rapid buildup of skin cells, resulting in the characteristic red, scaly patches. The exact cause of psoriasis is unknown, but it is believed to be a combination of genetic and environmental factors.
As of May, 15,300 prescribers had written more than 385,000 Vtama prescriptions, according to a Roivant earnings release. Selling off its specialized subsidiaries is nothing new for Roivant. Last October, the company agreed to a $7.1 billion deal for Swiss pharma giant Roche to acquire Telavant and its investigational antibody for inflammatory bowel disease, RVT-3101. The acquisition closed in December. Meanwhile, Organon has been on a dealmaking streak of its own in recent months. Following the $50 million purchase of European rights to two Eli Lilly migraine medicines in December, Organon’s CEO, Kevin Ali, said the deal was “not a one-off,” during an earnings call in February.
“There’s plenty in the queue that ultimately we can go after that are really nice opportunities for continuing revenue growth and [earnings] growth,” the CEO said at the time. In August, Organon upped its migraine accord with Lilly to the tune of $22.5 million, expanding its licensing pact to become the sole promoter and distributor of Emgality (included in the original EU deal) in Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates.
